Conjugates for treating diseases caused by psma expressing cells
AssigneeEndocyte, Inc.
InventorsIontcho Radoslavov VLAHOV, Joseph Anand REDDY, Alicia BLOOMFIELD, Ryan DORTON, Melissa NELSON, Marilynn VETZEL, Christopher Paul LEAMON
Life of this patent
Estimating the term…
Abstract
The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
Claims21
1-29. (canceled)
A conjugate of the formula
- B-L-D
- or a pharmaceutically acceptable salt thereof, wherein:
- B is of the formula
- L is a divalent linker comprising (i) one alkylenecarbonyl substituted with an arylalkyl, wherein the aryl is naphthyl, (ii) one or more radicals independently selected from the group consisting of an alkylene, a cycloalkylene, an alkylenecycloalkyl, and a cycloalkylenecarbonyl, and (iii) one or more heteroatom linkers selected from the group consisting of —NH—, —O—, and S;
- and
- D is a radioactive isotope of a metal coordinated to a chelating group, wherein the chelating group is covalently attached to L, and B is covalently attached to L.
The conjugate or the pharmaceutically acceptable salt thereof of 30, wherein L forms an amide bond with the lysine in B.
A conjugate of the formula
- B-L-D
- or a pharmaceutically acceptable salt thereof, wherein:
- B is of the formula
- L is a divalent linker, wherein L consists of (i) one alkylenecarbonyl substituted with 2-napthyl, (ii) a cycloalkylenecarbonyl, and (iii) one or more heteroatom linkers selected from the group consisting of —NH—, —O—, and S;
- and
- D is a radioactive isotope of a metal coordinated to a chelating group, wherein the chelating group is covalently attached to L, and B is covalently attached to L.
Dependencies are inferred from the claim text.